Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2088581
Max Phase: Preclinical
Molecular Formula: C25H18F3N3O3
Molecular Weight: 465.43
Molecule Type: Small molecule
Associated Items:
ID: ALA2088581
Max Phase: Preclinical
Molecular Formula: C25H18F3N3O3
Molecular Weight: 465.43
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(c1ccc(F)c(-c2c(=O)ccn3nc(Oc4ccc(F)cc4F)ccc23)c1)N1CCCC1
Standard InChI: InChI=1S/C25H18F3N3O3/c26-16-4-7-22(19(28)14-16)34-23-8-6-20-24(21(32)9-12-31(20)29-23)17-13-15(3-5-18(17)27)25(33)30-10-1-2-11-30/h3-9,12-14H,1-2,10-11H2
Standard InChI Key: JAHVLSUIOLCZNU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 465.43 | Molecular Weight (Monoisotopic): 465.1300 | AlogP: 4.81 | #Rotatable Bonds: 4 |
Polar Surface Area: 63.91 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.96 | CX LogD: 3.96 |
Aromatic Rings: 4 | Heavy Atoms: 34 | QED Weighted: 0.43 | Np Likeness Score: -1.60 |
1. Tynebor RM, Chen MH, Natarajan SR, O'Neill EA, Thompson JE, Fitzgerald CE, O'Keefe SJ, Doherty JB.. (2012) Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2., 22 (18): [PMID:22901390] [10.1016/j.bmcl.2012.07.035] |
Source(1):